Aqueous iron carbohydrate complexes, their production and medicaments containing them
A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.
1. An iron (III) carboxymaltodextrin complex wherein said iron (III) carboxymaltodextrin complex comprises polynuclear iron (III)-hydroxide 4(R)-(poly-(1→4)-O-α-D-glucopyranosyl)-oxy-2(R),3(R),5(R),6-tetrahydroxy-hexanoate and has a weight average molecular weight in the range of from 118 kDa to 271 kDa as measured by gel permeation chromatography, and wherein said 4(R)-(poly-(1→4)-O-α-D-glucopyranosyl)-oxy-2(R),3(R),5(R),6-tetrahydroxy-hexanoate is derived from the oxidation of maltodextrin, wherein when one maltodextrin is applied its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrins contained in the mixture lies between 2 and 40.
2. The iron (III) carboxymaltodextrin complex of claim 1 , wherein the oxidized maltodextrin is obtained by oxidation of maltodextrin in an aqueous hypochlorite solution.
3. A medicament comprising the iron (III) carboxymaltodextrin complex of claim 1 and at least one pharmaceutically acceptable carrier, excipient, or additive, wherein said medicament is an aqueous solution of said iron (III) carboxymaltodextrin complex.
4. The medicament of claim 3 , wherein said iron (III) carboxymaltodextrin complex is present in said aqueous solution in an amount of from 1% to 20% by weight, based on a total weight of the aqueous solution.
5. The medicament comprising the iron (III) carboxymaltodextrin complex of claim 3 , wherein the oxidized maltodextrin is obtained by oxidation of maltodextrin in an aqueous hypochlorite solution.
6. The medicament comprising the iron (III) carboxymaltodextrin complex of claim 5 , wherein said iron (III) carboxymaltodextrin complex is present in said aqueous solution in an amount of from 1% to 20% by weight, based on a total weight of the aqueous solution.
7. The medicament of claim 3 , wherein the aqueous solution has been sterilized at a temperature of 121° C. and above.
8. The medicament of claim 4 , wherein the aqueous solution has been sterilized at a temperature of 121° C. and above.
9. The medicament of claim 5 , wherein the aqueous solution has been sterilized at a temperature of 121° C. and above.
10. The medicament of claim 6 , wherein the aqueous solution has been sterilized at a temperature of 121° C. and above.
11. The medicament of claim 4 for parenteral administration to a subject in need thereof in the form of a single dose of 500 mg to 1000 mg of iron.
12. The medicament of claim 8 for parenteral administration to a subject in need thereof in the form of a single dose of 500 mg to 1000 mg of iron.
13. The medicament of claim 9 for parenteral administration to a subject in need thereof in the form of a single dose of 500 mg to 1000 mg of iron.
14. The medicament of claim 10 for parenteral administration to a subject in need thereof in the form of a single dose of 500 mg to 1000 mg of iron.
15. The medicament of claim 4 , wherein the iron (III) carboxymaltodextrin complex has a weight average molecular weight of: about 141,000 Da, or about 140,000 Da, or about 189,000 Da, or about 178,000 Da, or about 137,000 Da, or about 170,000 Da.
16. The medicament of claim 6 , wherein the iron (III) carboxymaltodextrin complex has a weight average molecular weight of: about 141,000 Da, or about 140,000 Da, or about 189,000 Da, or about 178,000 Da, or about 137,000 Da, or about 170,000 Da.
17. The medicament of claim 10 , wherein the iron (III) carboxymaltodextrin complex has a weight average molecular weight of: about 141,000 Da, or about 140,000 Da, or about 189,000 Da, or about 178,000 Da, or about 137,000 Da, or about 170,000 Da.
18. A method for treating an iron deficiency condition in a subject in need thereof, the method comprising administering to the subject in need thereof a pharmaceutically effective amount of a medicament of claim 3 , wherein the iron deficiency condition is anemia.
19. The method of claim 18 , wherein said medicament is administered (i) intravenously, (ii) by injection, or (iii) by infusion.
20. The method of claim 18 , wherein the subject is a human.
21. The method of claim 19 , wherein the subject is a human.